A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
09
2018
accepted:
04
03
2019
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
epublish
Résumé
We investigated the potential of in-depth quantitative plasma proteome analysis to uncover proteins predictive of progression and metastasis in triple negative breast cancer (TNBC). Analysis of samples from 24 pre-menopausal and 24 post-menopausal women with newly diagnosed TNBC who subsequently developed metastasis or remained metastasis free were utilized in the proteomic discovery set, which resulted in 43 proteins associated with tumor progression. These proteins were found to form a hierarchical network with TGFβ. The signature was further confirmed and refined by integrating plasma protein data from a murine TNBC model that encompassed mice with rapid- versus slow-growing tumors. Three genes consisting of CLIC1, MAPRE1, and SERPINA3 in the refined TGFβ signature significantly stratified overall survival (log-rank
Identifiants
pubmed: 30963111
doi: 10.1038/s41698-019-0082-5
pii: 82
pmc: PMC6445093
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA141539
Pays : United States
Déclaration de conflit d'intérêts
M.L.D. has an ownership interest with University of Washington over $10,000 and consultant positions with VentiRX, Roche, BMS, EMD, Serono and Immunovaccine. The authors declare no competing interests.
Références
Nat Med. 2000 May;6(5):556-63
pubmed: 10802712
Nature. 2000 Jul 27;406(6794):378-82
pubmed: 10935628
Mol Cell. 2003 Apr;11(4):915-26
pubmed: 12718878
Cancer Cell. 2003 Nov;4(5):405-13
pubmed: 14667507
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1491-5
pubmed: 1689487
Genome Biol. 2007;8(5):R76
pubmed: 17493263
J Biol Chem. 2008 Apr 18;283(16):10461-9
pubmed: 18250161
Cell. 2008 Apr 4;133(1):66-77
pubmed: 18394990
PLoS One. 2008 Jun 18;3(6):e2425
pubmed: 18560578
Cell Res. 2009 Jan;19(1):89-102
pubmed: 19050696
Nat Methods. 2009 Jan;6(1):83-90
pubmed: 19060904
Genes Chromosomes Cancer. 2009 Aug;48(8):679-93
pubmed: 19441093
Am J Pathol. 2009 Jun;174(6):2073-85
pubmed: 19465643
Bioinformatics. 2010 Sep 15;26(18):2347-8
pubmed: 20656902
Nat Rev Genet. 2011 Jan;12(1):56-68
pubmed: 21164525
EMBO J. 2011 Feb 16;30(4):783-95
pubmed: 21224849
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Cell. 2012 Aug 3;150(3):549-62
pubmed: 22863008
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2013;8(2):e56587
pubmed: 23437179
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Cell. 2014 Jul 31;158(3):564-78
pubmed: 25083868
Mol Cancer Res. 2015 Feb;13(2):273-80
pubmed: 25205595
Nucleic Acids Res. 2015 Jan;43(Database issue):D204-12
pubmed: 25348405
Breast Cancer Res Treat. 2014 Dec;148(3):501-10
pubmed: 25395320
Oncogene. 2016 Apr 14;35(15):1888-98
pubmed: 26148233
Cancer Prev Res (Phila). 2015 Nov;8(11):1112-9
pubmed: 26342024
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69
pubmed: 26694831
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Oncogenesis. 2017 Jul 10;6(7):e360
pubmed: 28692037
Dig Dis Sci. 2018 Sep;63(9):2309-2319
pubmed: 29855767